Etomidate
Etomidate has been studied in 2 papers since 2024: 2 trials in people; 1 in the past year. The newest paper, Nov 8, 2026: “Optimal Etomidate Induction Dosage Combined With Nerve Block Minimizes Postoperative Cognitive Dysfunction and Enhances Hemodynamic Stability in Elderly Hernia Patients”.
1 new paper in 30 daysSee all 6 papers on etomidate
At a glance
The findings reach people, from one lab or study. 1 lab; 1 trial, none about aging.
“The medium-dose group showed superior hemodynamic stability with smaller fluctuations in mean arterial pressure (MAP), systolic blood pressure (SBP), and heart rate (HR)”
None of its findings points the other way.
- 1 lab
- 1 trial, none about aging
- Human trial2
Studies in people
1 study gave etomidate to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Improves hemodynamic stability down: Decreases postoperative cognitive dysfunction8.3% POCD rate on day 1 in the medium-dose group down: Decreases adverse events13.9% adverse events in the medium-dose group | Randomized trialintraoperative | 36 peopleelderlyOlder adults; hernia surgery with nerve block, sufentanil, and remimazolam | The Annals of pharmacotherapy, Nov 8, 2026 |
What did studies of etomidate find?
3Studies of etomidate measured 3 outcomes: adverse events, postoperative cognitive dysfunction and hemodynamic stability.
Adverse events
downin humans1−14% adverse events in the medium-dose group
1 study
Adverse events
downin humans1−14% adverse events in the medium-dose group
Etomidate decreases adverse events in humans (13.9% adverse events in the medium-dose group).
“Etomidate 0.2 mg/kg with nerve block achieves favorable hemodynamics and minimizes POCD and adverse reactions in elderly hernia surgery”
Human trialhernia surgery with nerve block, sufentanil, and remimazolam; compared with low- and high-dose etomidate0.2 mg/kgn = 36
The Annals of pharmacotherapy
Postoperative cognitive dysfunction
downin humans1
1 study
Postoperative cognitive dysfunction
downin humans1
Etomidate decreases postoperative cognitive dysfunction in humans (8.3% POCD rate on day 1 in the medium-dose group).
“Etomidate 0.2 mg/kg with nerve block achieves favorable hemodynamics and minimizes POCD and adverse reactions in elderly hernia surgery”
Human trialhernia surgery with nerve block, sufentanil, and remimazolam; compared with low- and high-dose etomidate0.2 mg/kgpostoperative day 1n = 36
The Annals of pharmacotherapy
Hemodynamic stability
upin humans1
1 study
Hemodynamic stability
upin humans1
Etomidate improves hemodynamic stability in humans.
“The medium-dose group showed superior hemodynamic stability with smaller fluctuations in mean arterial pressure (MAP), systolic blood pressure (SBP), and heart rate (HR)”
Human trialhernia surgery with nerve block, sufentanil, and remimazolam; compared with low- and high-dose etomidate0.2 mg/kgintraoperativen = 36
The Annals of pharmacotherapy
Trial sponsors
Universitaire Ziekenhuizen KU Leuven
1 trial110 people